Tag:
Ian Read
Latest Headlines
Latest Headlines
How does pharma's CEO pay rank?
We know how pharma CEO pay stacked up within the industry. But how did pharma's 2011 compensation packages compare with those in other industries?
Pfizer scouts for bite-sized buyouts after Lipitor sales wilt
Followers of Pfizer won't be surprised to learn of Read's M&A appetite, yet the pharma chief happens to be scouting for deals at an interesting time in the industry and at his company.
WSJ: Pfizer poised to sell nutrition biz to Nestlé for $9B-plus
Besides Nestlé, Pfizer had been entertaining offers from Danone and Mead Johnson Nutrition in auctioning off the unit.
UPDATED: Pfizer shrinking severance pay amid major cutbacks
Ian Read has vowed to cut $1 billion in operating expenses at the drugmaker this year, and one way he plans to do that appears to be by reducing severance packages.
Pfizer open to Abbott-style split, analyst says
Is Pfizer pursuing a full-scale breakup strategy, just on the down low and on the long finger?
After slashing jobs, Pfizer CEO Ian Read draws $25M
As Bloomberg reports, the Pfizer board rewarded CEO Ian Read with a $25 million paycheck.
Divestments 'not a trivial exercise,' Read tells FT
Pfizer ( $PFE ) CEO Ian Read ( photo ) told the Financial Times that he hopes to divest the company's animal health and nutrition units by June 13.
Pfizer weighing baby-formula offers from Nestle, Danone
Pfizer ( $PFE ) has collected first-round bids for its nutritionals unit, sources tell Bloomberg, and food giants Nestle ( $NESN ) and Danone ($BN) are among them. The drugmaker is planning to divest
Shrinking Pfizer targeting new round of small, tailor-made buyouts and pacts
Pfizer is thinking small these days. In keeping with the deal-making theme at the J.P. Morgan conference, Pfizer ( $PFE ) CEO Ian Read carefully mapped out the pharma giant's near-term strategy, with
Pfizer elects CEO Read as company chair
Pfizer ( $PFE ) has elected CEO Ian Read ( photo ) as chairman of the board. Read succeeds George Lorch, who was named lead independent director. "Over the past year, Ian has clearly demonstrated the
